{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-048516","form_type":"8-K","ticker":"INFU","cik":"0001337013","company_name":"InfuSystem Holdings, Inc","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.183954+00:00","generated_at":"2026-05-17T00:34:36.501889+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"InfuSystem Q3 2025 revenue $36.5M (+3% YoY), net income $2.3M (+25%), reaffirms 2025 guidance","bullets":["Net revenues $36.5M (record), up 3% vs. $35.3M a year ago; Patient Services up 8%, Device Solutions down 3%.","Net income $2.3M ($0.11 diluted EPS) vs. $1.8M ($0.08) prior year, a 25% increase.","Adjusted EBITDA $8.3M (+6%), margin 22.8% (up 0.5pp); YTD operating cash flow $17.3M (+38%).","Wound care revenue surged 115% YoY ($1.0M); new contract with large hospital system and payer extension secured.","Reaffirms full-year 2025 guidance: net revenue growth 6-8%, Adjusted EBITDA margin 20%+."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-048516","json":"https://secwatch.observer/filing/0001628280-25-048516.json","markdown":"https://secwatch.observer/filing/0001628280-25-048516.md","text":"https://secwatch.observer/filing/0001628280-25-048516.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1337013/000162828025048516/0001628280-25-048516-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1337013/000162828025048516/infu-20251104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:34:36.501889+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}